The microbiome in allergic disease: Current understanding and future opportunities—2017 PRACTALL document of the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergy and Clinical Immunology - 19/04/17
Abstract |
PRACTALL is a joint initiative of the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergy and Clinical Immunology to provide shared evidence-based recommendations on cutting-edge topics in the field of allergy and immunology. PRACTALL 2017 is focused on what has been established regarding the role of the microbiome in patients with asthma, atopic dermatitis, and food allergy. This is complemented by outlining important knowledge gaps regarding its role in allergic disease and delineating strategies necessary to fill these gaps. In addition, a review of progress in approaches used to manipulate the microbiome will be addressed, identifying what has and has not worked to serve as a baseline for future directions to intervene in allergic disease development, progression, or both.
Le texte complet de cet article est disponible en PDF.Key words : Microbiome, microbiota, dysbiosis, asthma, atopic dermatitis, food allergy, systems biology, probiotic, prebiotic
Abbreviations used : AD, EH, SCFA
Plan
Supported in part by the National Institutes of Health (NIH) Intramural Program of the NIH Clinical Center. |
|
Disclosure of potential conflict of interest: Y. J. Huang has received travel support and payment for lectures from the American Academy of Allergy, Asthma & Immunology and has received travel support from the National Academy of Science, Engineering, and Medicine; the National Institutes of Health (NIH), the American College of Chest Physicians, the European Respiratory Society, and the Massachusetts Institute of Technology. S. Bunyavanich has received a grant from the NIH/National Institute of Allergy and Infectious Diseases. L. O'Mahony has consultant arrangements with Alimentary Health Ltd and has received grants from GlaxoSmithKline. D. Y. M. Leung has received a grant from MedImmune; has received consulting fees or honoraria from Novartis, Regeneron, and Sanofi-Aventis; and has received payment for writing or reviewing this manuscript from Omnia-Prova Education Collaborative. A. Muraro has consultant arrangements with Meda, Novartis, and Menarini; is employed by Padua University Hospital; and has received payment for lectures from Meda and Menarini. T. A. Fleisher is President of the American Academy of Allergy, Asthma & Immunology; has received payment for lectures from the Boston City Wide Allergy Meeting, the Louisiana Society of Allergy, Asthma, and Immunology, and the Alaska Society of Allergy, Asthma, and Immunology; and has received royalties as coeditor of Clinical Immunology: Principles and Practice. B. J. Marsland declares that he has no relevant conflicts of interest. |
Vol 139 - N° 4
P. 1099-1110 - avril 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?